Cyxone appoints Erika Samuelsson as Chief Development Officer
Cyxone (publ), a biotech company in autoimmune diseases, announces today that Erika Samuelsson has been appointed new Chief Development Officer (CDO) in the company as of 1 September 2022. With her broad experience from roles in project management in drug development within the biotech business, Erika will be an important part of Cyxone’s continued ambition to strengthen and develop the company.Erika Samuelsson holds a PhD in Immunology from Lund University and has over 20 years’ experience from the Life Science field. Erika has held senior positions at Alligator Bioscience AB, Idogen AB